Mirxes
Develops microRNA liquid biopsy tests for the early detection of gastric and other cancers.
What they do
Mirxes produces high-sensitivity blood-based microRNA PCR assays for early cancer detection. Healthcare institutions and clinical laboratories deploy its GASTROclear test to detect early-stage stomach cancers before symptoms manifest, improving patient survival rates through early intervention.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series C+
- Headquarters
- Singapore
- Region
- Asia-Pacific
- Founded
- 2014
- Total funding
- $177M raised
Notable investors: Rock Springs Capital, Banyan Tree Investment Group, CR-CP Life Science Fund, Beijing Venture Capital.